Drug Trial Radar · NCT07570173
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
May 18, 2026
Primary completion
Oct 18, 2033
Study completion Oct 18, 2033
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.
Conditions
- B-cell Acute Lymphoblastic Leukemia
Interventions
MK-1045Biological
Intravenous administration
BlinatumomabBiological
Intravenous administration
AcetaminophenDrug
Oral administration as a premedication
DiphenhydramineDrug
Intravenous administration as a premedication
DexamethasoneDrug
Intravenous administration as a premedication
TocilizumabDrug
Intravenous administration as a rescue medication
SiltuximabDrug
Intravenous administration as a rescue medication
AvtozmaDrug
Intravenous administration as a rescue medication
TyenneDrug
Intravenous administration as a rescue medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2Time frame: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
- Percentage of Participants Who Experience an Adverse Event (AE) in Study Part 1Time frame: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
- Percentage of Participants Who Discontinue Study Intervention Due to an AE in Study Part 1Time frame: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
- Overall Survival (OS) in Study Part 2Time frame: Up to approximately 7 years
Locations
30 sites in 10 countries. Site status is shown where the registry gives one.
Princess Margaret Cancer Center ( Site 0102)
Toronto, Ontario, Canada · Recruiting
Rigshospitalet ( Site 0802)
Copenhagen, Capital Region, Denmark · Recruiting
Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804)
Aarhus Nord, Central Jutland, Denmark · Recruiting
Odense Universitetshospital ( Site 0801)
Odense C, Region Syddanmark, Denmark · Recruiting
CHU Bordeaux Haut-Leveque ( Site 4103)
Pessac, Gironde, France · Recruiting
Hopital Saint-Louis ( Site 4100)
Paris, Île-de-France Region, France · Recruiting
University Hospital of Ioannina ( Site 5103)
Ioannina, Greece · Recruiting
Evangelismos General Hospital of Athens ( Site 5100)
Athens, Attica, Greece · Recruiting
General Hospital of Athens "Laiko" ( Site 5101)
Athens, Attica, Greece · Recruiting
General Hospital of Athens "Laiko" ( Site 5104)
Athens, Attica, Greece · Recruiting
University General Hospital ''Attikon'' - General Hospital of West Attica "H AGIA VARVARA" ( Site 5102)
Chaïdári, Attica, Greece · Recruiting
Rambam Health Care Campus ( Site 0903)
Haifa, Israel · Recruiting
Haddasah Medical Center ( Site 0900)
Jerusalem, Israel · Recruiting
Sheba Medical Center ( Site 0902)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center. ( Site 0904)
Tel Aviv, Israel · Recruiting
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 1002)
Bergamo, Lombardy, Italy · Recruiting
Policlinico Universitario Agostino Gemelli ( Site 1003)
Rome, Roma, Italy · Recruiting
Tokyo Metropolitan Komagome Hospital ( Site 2106)
Bunkyo, Tokyo, Japan · Recruiting
Toranomon Hospital ( Site 2101)
Minato, Tokyo, Japan · Recruiting
Radboud UMC ( Site 2003)
Geert Grooteplein-Zuid 8, Gelderland, Netherlands · Recruiting
Amsterdam UMC ( Site 2001)
Amsterdam, North Holland, Netherlands · Recruiting
Erasmus Medisch Centrum ( Site 2000)
Rotterdam, South Holland, Netherlands · Recruiting
Hospital General Universitario Gregorio Marañón ( Site 3003)
Madrid, Spain · Recruiting
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 3009)
Madrid, Spain · Recruiting
Hospital Universitario de Salamanca ( Site 3002)
Salamanca, Spain · Recruiting
Institut Català d'Oncologia (ICO) - Badalona ( Site 3001)
Badalona, Barcelona, Spain · Recruiting
Clinica Universidad de Navarra ( Site 3006)
Pamplona, Navarre, Spain · Recruiting
Hospital Universitario Central de Asturias ( Site 3008)
Oviedo, Principality of Asturias, Spain · Recruiting
HOSPITAL CLINICO DE VALENCIA ( Site 3005)
Valencia, Valenciana, Comunitat, Spain · Recruiting
Karolinska Universitetssjukhuset ( Site 4002)
Stockholm, Stockholm County, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.